title: Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.
abstract: The classical myeloproliferative neoplasms (MPNs) are a group of clonal diseases comprising essential thrombocythaemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF). PMF is the rarest disease sub type and has been challenging to address due to the lack of a specific genetic marker, inadequate risk identification models and a highly variable clinical course. Continuous efforts have over time, seen the inclusion of cytogenetic information in prognostic scoring models that have resulted in improved risk stratification models providing further rationale for therapeutic management. Technological advances using single nucleotide polymorphism arrays increased the detection of known and novel MPN related changes and variant detection by massively parallel sequencing provided a large scale screening tool for the multitude of somatic gene mutations that have more recently been described in MPN. Some of these mutations show an association with specific cytogenetic changes or phenotypes. While PMF occurs mainly in adults, it has also been described in paediatric cases and shows distinct histopathological, genetic and clinical features in comparison. This review provides an overview of the genomics landscape of PMF and current developments in MPN therapy.
authors.affiliation: 1 Department of Genetics, Pathology North-Sydney, St Leonards, NSW, Australia ; 2 Kolling Institute, University of Sydney, NSW, Australia.
authors.forename: Nisha R
authors.initials: NR
authors.lastname: Singh
keywords: Myeloproliferative neoplasm (MPN); gene mutations; primary myelofibrosis (PMF)
references.citation: Blood. 2005 Sep 15;106(6):2162-8
references.pmid: 15920007
references.citation: Oncotarget. 2011 Jun;2(6):485-90
references.pmid: 21646683
references.citation: Eur J Haematol. 2010 Mar;84(3):191-200
references.pmid: 20002154
references.citation: Hematol Oncol Clin North Am. 2012 Oct;26(5):1037-51
references.pmid: 23009936
references.citation: N Engl J Med. 2013 Dec 19;369(25):2379-90
references.pmid: 24325356
references.citation: Cancer Cell. 2005 Apr;7(4):387-97
references.pmid: 15837627
references.citation: Exp Hematol. 2008 Nov;36(11):1471-9
references.pmid: 18723266
references.citation: N Engl J Med. 2010 Sep 16;363(12):1117-27
references.pmid: 20843246
references.citation: J Dermatol. 2008 Jul;35(7):456-61
references.pmid: 18705835
references.citation: Eur J Haematol Suppl. 2007 Oct;(68):2-4
references.pmid: 17727556
references.citation: Pediatr Blood Cancer. 2014 Dec;61(12):2256-62
references.pmid: 25176567
references.citation: Leuk Res. 2007 Jul;31(7):883-6
references.pmid: 17303238
references.citation: Leukemia. 2010 Oct;24(10 ):1799-804
references.pmid: 20724984
references.citation: Science. 2014 Nov 28;346(6213):1258096
references.pmid: 25430774
references.citation: N Engl J Med. 2003 Mar 27;348(13):1201-14
references.pmid: 12660384
references.citation: Haematologica. 2013 Oct;98(10):1499-509
references.pmid: 24091929
references.citation: N Engl J Med. 2009 May 28;360(22):2289-301
references.pmid: 19474426
references.citation: N Engl J Med. 2013 Dec 19;369(25):2391-405
references.pmid: 24325359
references.citation: Leukemia. 2008 Jul;22(7):1299-307
references.pmid: 18496562
references.citation: Blood. 2011 Aug 18;118(7):1723-35
references.pmid: 21653328
references.citation: Mol Cytogenet. 2013 Dec 17;6(1):59
references.pmid: 24341401
references.citation: Br J Haematol. 2015 Apr;169(1):71-6
references.pmid: 25521305
references.citation: Blood. 2009 Jun 11;113(24):6182-92
references.pmid: 19387008
references.citation: Leuk Res. 2008 Nov;32(11):1783-6
references.pmid: 18455791
references.citation: Nat Genet. 2010 Aug;42(8):665-7
references.pmid: 20601954
references.citation: Br J Haematol. 2005 Mar;128(5):690-7
references.pmid: 15725091
references.citation: Leukemia. 2014 Feb;28(2):431-3
references.pmid: 24097336
references.citation: Am J Hematol. 2012 May;87(5):461-4
references.pmid: 22389089
references.citation: Hematology Am Soc Hematol Educ Program. 2005;:195-200
references.pmid: 16304380
references.citation: Blood. 2009 Dec 10;114(25):5201-5
references.pmid: 19850737
references.citation: Blood. 2011 May 26;117(21):5612-5
references.pmid: 21450904
references.citation: Rev Bras Hematol Hemoter. 2012;34(2):150-5
references.pmid: 23049405
references.citation: Leukemia. 2010 Jun;24(6):1128-38
references.pmid: 20428194
references.citation: N Engl J Med. 2000 Apr 27;342(17):1255-65
references.pmid: 10781623
references.citation: Blood. 2012 Nov 15;120(20):4168-71
references.pmid: 22968464
references.citation: Leukemia. 2011 Jul;25(7):1219-20
references.pmid: 21519343
references.citation: N Engl J Med. 2005 Apr 28;352(17):1779-90
references.pmid: 15858187
references.citation: Blood. 2005 Feb 1;105(3):973-7
references.pmid: 15388582
references.citation: Blood. 2010 Apr 8;115(14 ):2891-900
references.pmid: 20008300
references.citation: Lancet. 2005 Mar 19-25;365(9464):1054-61
references.pmid: 15781101
references.citation: Blood. 2008 Jul 1;112(1):141-9
references.pmid: 18451306
references.citation: Leukemia. 2008 Apr;22(4):756-61
references.pmid: 18216871
references.citation: Haematologica. 2010 Apr;95(4):666-9
references.pmid: 20015882
references.citation: PLoS One. 2007 Nov 21;2(11):e1225
references.pmid: 18030353
references.citation: PLoS Med. 2006 Jul;3(7):e270
references.pmid: 16834459
references.citation: Leukemia. 2010 Oct;24(10):1713-8
references.pmid: 20724988
references.citation: Eur J Haematol. 2008 Mar;80(3):197-200
references.pmid: 18081705
references.citation: Br J Haematol. 2001 Jun;113(3):763-71
references.pmid: 11380468
references.citation: Leukemia. 2008 Aug;22(8):1557-66
references.pmid: 18528423
references.citation: J Clin Oncol. 2011 Feb 1;29(4):392-7
references.pmid: 21149668
references.citation: Histol Histopathol. 2006 Dec;21(12):1367-78
references.pmid: 16977587
references.citation: Nature. 2005 Apr 28;434(7037):1144-8
references.pmid: 15793561
references.citation: Leukemia. 2015 Jan;29(1):253-5
references.pmid: 25231745
references.citation: Blood. 2009 Aug 20;114(8):1477-83
references.pmid: 19549988
references.citation: Leukemia. 2010 Jun;24(6):1146-51
references.pmid: 20410924
references.citation: J Clin Oncol. 1999 Sep;17(9):2954-70
references.pmid: 10561375
references.citation: Ann Hematol. 2005 Apr;84(4):250-7
references.pmid: 15692838
references.citation: J Clin Oncol. 2005 Nov 20;23(33):8520-30
references.pmid: 16293880
references.citation: Br J Haematol. 2004 Nov;127(4):399-403
references.pmid: 15521916
references.citation: Blood. 2012 May 10;119(19):4480-5
references.pmid: 22431577
references.citation: Blood. 2012 Mar 22;119(12):2721-30
references.pmid: 22279053
references.citation: J Exp Med. 2013 May 6;210(5):1003-19
references.pmid: 23589569
references.citation: Ther Adv Hematol. 2012 Jun;3(3):131-46
references.pmid: 23556120
references.citation: Mol Ther. 2015 Mar;23(3):570-7
references.pmid: 25418680
references.citation: Semin Oncol. 2005 Aug;32(4):395-402
references.pmid: 16202685